Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Logo for

Science 312 (5777): 1175-1178

Copyright © 2006 by the American Association for the Advancement of Science

Targeting Tyrosine Kinases in Cancer: The Second Wave

Jose Baselga

Abstract: One of the most exciting developments in cancer research in recent years has been the clinical validation of molecularly targeted drugs that inhibit the action of pathogenic tyrosine kinases. Treatment of appropriately selected patients with these drugs can alter the natural history of their disease and improve survival. The clinical validation of these "first-generation" tyrosine kinase inhibitors has been the prelude to a second wave of advances in molecular targeting that is expected to further change the way we classify and treat cancer. Efforts are now being directed at identifying the tumor subtypes and patients who will benefit the most from these drugs. In addition, new compounds that circumvent acquired resistance to the first-generation tyrosine kinase inhibitors are being tested in patients with refractory disease. Agents directed against new molecular targets are also being explored.

Oncology Program, Vall d'Hebron University Hospital and Vall d'Hebron Research Institute, Universidad Autónoma de Barcelona, Barcelona 08035, Spain.

E-mail: jbaselga{at}

Gene network dynamics controlling keratinocyte migration.
H. Busch, D. Camacho-Trullio, Z. Rogon, K. Breuhahn, P. Angel, R. Eils, and A. Szabowski (2014)
Mol Syst Biol 4, 199
   Abstract »    Full Text »    PDF »
Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy.
I. Amit, R. Wides, and Y. Yarden (2014)
Mol Syst Biol 3, 151
   Abstract »    Full Text »    PDF »
New Chemical Scaffolds for Human African Trypanosomiasis Lead Discovery from a Screen of Tyrosine Kinase Inhibitor Drugs.
R. Behera, S. M. Thomas, and K. Mensa-Wilmot (2014)
Antimicrob. Agents Chemother. 58, 2202-2210
   Abstract »    Full Text »    PDF »
Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer.
Z. A. Wainberg, A. Anghel, A. M. Rogers, A. J. Desai, O. Kalous, D. Conklin, R. Ayala, N. A. O'Brien, C. Quadt, M. Akimov, et al. (2013)
Mol. Cancer Ther. 12, 509-519
   Abstract »    Full Text »    PDF »
Emerging Roles of SIRT1 in Cancer Drug Resistance.
Z. Wang and W. Chen (2013)
Genes & Cancer 4, 82-90
   Abstract »    Full Text »    PDF »
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer.
R. Bose, S. M. Kavuri, A. C. Searleman, W. Shen, D. Shen, D. C. Koboldt, J. Monsey, N. Goel, A. B. Aronson, S. Li, et al. (2013)
Cancer Discovery 3, 224-237
   Abstract »    Full Text »    PDF »
STK31 Maintains the Undifferentiated State of Colon Cancer Cells.
K. L. Fok, C. M. Chung, S. Q. Yi, X. Jiang, X. Sun, H. Chen, Y. C. Chen, H.-F. Kung, Q. Tao, R. Diao, et al. (2012)
Carcinogenesis 33, 2044-2053
   Abstract »    Full Text »    PDF »
Superbinder SH2 Domains Act as Antagonists of Cell Signaling.
T. Kaneko, H. Huang, X. Cao, X. Li, C. Li, C. Voss, S. S. Sidhu, and S. S. C. Li (2012)
Science Signaling 5, ra68
   Abstract »    Full Text »    PDF »
Phosphoproteomic Analysis of Leukemia Cells under Basal and Drug-treated Conditions Identifies Markers of Kinase Pathway Activation and Mechanisms of Resistance.
M. P. Alcolea, P. Casado, J.-C. Rodriguez-Prados, B. Vanhaesebroeck, and P. R. Cutillas (2012)
Mol. Cell. Proteomics 11, 453-466
   Abstract »    Full Text »    PDF »
Phosphoproteomics Identifies Driver Tyrosine Kinases in Sarcoma Cell Lines and Tumors.
Y. Bai, J. Li, B. Fang, A. Edwards, G. Zhang, M. Bui, S. Eschrich, S. Altiok, J. Koomen, and E. B. Haura (2012)
Cancer Res. 72, 2501-2511
   Abstract »    Full Text »    PDF »
Deciphering Phosphotyrosine-Dependent Signaling Networks in Cancer by SH2 Profiling.
K. Machida, M. Khenkhar, and P. Nollau (2012)
Genes & Cancer 3, 353-361
   Abstract »    Full Text »    PDF »
Differential Sensitivity of Glioma- versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors.
I. Vivanco, H. I. Robins, D. Rohle, C. Campos, C. Grommes, P. L. Nghiemphu, S. Kubek, B. Oldrini, M. G. Chheda, N. Yannuzzi, et al. (2012)
Cancer Discovery 2, 458-471
   Abstract »    Full Text »    PDF »
Can Intensive Longitudinal Monitoring of Individuals Advance Cancer Research?.
C. A. Blau (2012)
Oncologist 17, 587-589
   Full Text »    PDF »
Consistency Test of the Cell Cycle: Roles for p53 and EGR1.
Y. Zwang, M. Oren, and Y. Yarden (2012)
Cancer Res. 72, 1051-1054
   Abstract »    Full Text »    PDF »
Epigenetic Silencing of MicroRNA-203 Dysregulates ABL1 Expression and Drives Helicobacter-Associated Gastric Lymphomagenesis.
V. J. Craig, S. B. Cogliatti, H. Rehrauer, T. Wundisch, and A. Muller (2011)
Cancer Res. 71, 3616-3624
   Abstract »    Full Text »    PDF »
Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer.
M. Scaltriti, V. Serra, E. Normant, M. Guzman, O. Rodriguez, A. R. Lim, K. L. Slocum, K. A. West, V. Rodriguez, L. Prudkin, et al. (2011)
Mol. Cancer Ther. 10, 817-824
   Abstract »    Full Text »    PDF »
Combination Treatment with HER-2 and VEGF Peptide Mimics Induces Potent Anti-tumor and Anti-angiogenic Responses in Vitro and in Vivo.
K. C. Foy, Z. Liu, G. Phillips, M. Miller, and P. T. P. Kaumaya (2011)
J. Biol. Chem. 286, 13626-13637
   Abstract »    Full Text »    PDF »
Polymalic Acid-Based Nanobiopolymer Provides Efficient Systemic Breast Cancer Treatment by Inhibiting both HER2/neu Receptor Synthesis and Activity.
S. Inoue, H. Ding, J. Portilla-Arias, J. Hu, B. Konda, M. Fujita, A. Espinoza, S. Suhane, M. Riley, M. Gates, et al. (2011)
Cancer Res. 71, 1454-1464
   Abstract »    Full Text »    PDF »
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
D. Vitagliano, V. De Falco, A. Tamburrino, S. Coluzzi, G. Troncone, G. Chiappetta, F. Ciardiello, G. Tortora, J. A. Fagin, A. J. Ryan, et al. (2011)
Endocr. Relat. Cancer 18, 1-11
   Abstract »    Full Text »    PDF »
Kinase-mediated quasi-dimers of EGFR.
E. M. Bublil, G. Pines, G. Patel, G. Fruhwirth, T. Ng, and Y. Yarden (2010)
FASEB J 24, 4744-4755
   Abstract »    Full Text »    PDF »
Anticolon Cancer Activity of Largazole, a Marine-Derived Tunable Histone Deacetylase Inhibitor.
Y. Liu, L. A. Salvador, S. Byeon, Y. Ying, J. C. Kwan, B. K. Law, J. Hong, and H. Luesch (2010)
J. Pharmacol. Exp. Ther. 335, 351-361
   Abstract »    Full Text »    PDF »
Targeted Nanoparticles That Deliver a Sustained, Specific Release of Paclitaxel to Irradiated Tumors.
R. J. Passarella, D. E. Spratt, A. E. van der Ende, J. G. Phillips, H. Wu, V. Sathiyakumar, L. Zhou, D. E. Hallahan, E. Harth, and R. Diaz (2010)
Cancer Res. 70, 4550-4559
   Abstract »    Full Text »    PDF »
Oncogenic Signal Transduction Networks in Cancer: Relevance to Cancer Therapy.
E. Bublil, C. R. Pradeep, and Y. Yarden (2010)
Am. Assoc. Cancer Res. Educ. Book 2010, 39-42
   Full Text »    PDF »
Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development.
A. M. Gustafson, R. Soldi, C. Anderlind, M. B. Scholand, J. Qian, X. Zhang, K. Cooper, D. Walker, A. McWilliams, G. Liu, et al. (2010)
Science Translational Medicine 2, 26ra25
   Abstract »    Full Text »    PDF »
Roles for Growth Factors in Cancer Progression.
E. Witsch, M. Sela, and Y. Yarden (2010)
Physiology 25, 85-101
   Abstract »    Full Text »    PDF »
From combinatorial peptide selection to drug prototype (II): Targeting the epidermal growth factor receptor pathway.
M. Cardo-Vila, R. J. Giordano, R. L. Sidman, L. F. Bronk, Z. Fan, J. Mendelsohn, W. Arap, and R. Pasqualini (2010)
PNAS 107, 5118-5123
   Abstract »    Full Text »    PDF »
Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo.
Z. A. Wainberg, A. Anghel, A. J. Desai, R. Ayala, T. Luo, B. Safran, M. S. Fejzo, J. R. Hecht, D. J. Slamon, and R. S. Finn (2010)
Clin. Cancer Res. 16, 1509-1519
   Abstract »    Full Text »    PDF »
Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside.
J. Rodon, J. Perez, and R. Kurzrock (2010)
Oncologist 15, 37-50
   Abstract »    Full Text »    PDF »
Strategies for Molecular Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in Cancer.
E. Mishani and A. Hagooly (2009)
J. Nucl. Med. 50, 1199-1202
   Abstract »    Full Text »    PDF »
Apratoxin A Reversibly Inhibits the Secretory Pathway by Preventing Cotranslational Translocation.
Y. Liu, B. K. Law, and H. Luesch (2009)
Mol. Pharmacol. 76, 91-104
   Abstract »    Full Text »    PDF »
Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy.
H. Jarvelainen, A. Sainio, M. Koulu, T. N. Wight, and R. Penttinen (2009)
Pharmacol. Rev. 61, 198-223
   Abstract »    Full Text »    PDF »
Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories.
S. Yang, N. K. Banavali, and B. Roux (2009)
PNAS 106, 3776-3781
   Abstract »    Full Text »    PDF »
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.
F. Carlomagno, T. Guida, S. Anaganti, L. Provitera, S. Kjaer, N. Q McDonald, A. J Ryan, and M. Santoro (2009)
Endocr. Relat. Cancer 16, 233-241
   Abstract »    Full Text »    PDF »
High-Throughput Biochemical Kinase Selectivity Assays: Panel Development and Screening Applications.
A. Card, C. Caldwell, H. Min, B. Lokchander, Hualin Xi, S. Sciabola, A. V. Kamath, S. L. Clugston, W. R. Tschantz, Leyu Wang, et al. (2009)
J Biomol Screen 14, 31-42
   Abstract »    PDF »
Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors.
P. Ross-Macdonald, H. de Silva, Q. Guo, H. Xiao, C.-Y. Hung, B. Penhallow, J. Markwalder, L. He, R. M. Attar, T.-a. Lin, et al. (2008)
Mol. Cancer Ther. 7, 3490-3498
   Abstract »    Full Text »    PDF »
N-Glycans in cancer progression.
K. S Lau and J. W Dennis (2008)
Glycobiology 18, 750-760
   Abstract »    Full Text »    PDF »
Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies.
M. Dechant, W. Weisner, S. Berger, M. Peipp, T. Beyer, T. Schneider-Merck, J. J. Lammerts van Bueren, W. K. Bleeker, P. W.H.I. Parren, J. G.J. van de Winkel, et al. (2008)
Cancer Res. 68, 4998-5003
   Abstract »    Full Text »    PDF »
Eight-channel iTRAQ Enables Comparison of the Activity of Six Leukemogenic Tyrosine Kinases.
A. Pierce, R. D. Unwin, C. A. Evans, S. Griffiths, L. Carney, L. Zhang, E. Jaworska, C.-F. Lee, D. Blinco, M. J. Okoniewski, et al. (2008)
Mol. Cell. Proteomics 7, 853-863
   Abstract »    Full Text »    PDF »
An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors.
P. Accornero, G. Lattanzio, T. Mangano, R. Chiarle, R. Taulli, F. Bersani, P. E. Forni, S. Miretti, C. Scuoppo, W. Dastru, et al. (2008)
Clin. Cancer Res. 14, 2220-2226
   Abstract »    Full Text »    PDF »
Prediction of Cancer Driver Mutations in Protein Kinases.
A. Torkamani and N. J. Schork (2008)
Cancer Res. 68, 1675-1682
   Abstract »    Full Text »    PDF »
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
J. Tsai, J. T. Lee, W. Wang, J. Zhang, H. Cho, S. Mamo, R. Bremer, S. Gillette, J. Kong, N. K. Haass, et al. (2008)
PNAS 105, 3041-3046
   Abstract »    Full Text »    PDF »
Imaging Epidermal Growth Factor Receptor Expression In vivo: Pharmacokinetic and Biodistribution Characterization of a Bioconjugated Quantum Dot Nanoprobe.
P. Diagaradjane, J. M. Orenstein-Cardona, N. E. Colon-Casasnovas, A. Deorukhkar, S. Shentu, N. Kuno, D. L. Schwartz, J. G. Gelovani, and S. Krishnan (2008)
Clin. Cancer Res. 14, 731-741
   Abstract »    Full Text »    PDF »
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib.
T. M. Gilmer, L. Cable, K. Alligood, D. Rusnak, G. Spehar, K. T. Gallagher, E. Woldu, H. L. Carter, A. T. Truesdale, L. Shewchuk, et al. (2008)
Cancer Res. 68, 571-579
   Abstract »    Full Text »    PDF »
Reinduction of ErbB2 in astrocytes promotes radial glial progenitor identity in adult cerebral cortex.
H.T. Ghashghaei, J. M. Weimer, R. S. Schmid, Y. Yokota, K. D. McCarthy, B. Popko, and E.S. Anton (2007)
Genes & Dev. 21, 3258-3271
   Abstract »    Full Text »    PDF »
In Situ Detection of Phosphorylated Platelet-derived Growth Factor Receptor {beta} Using a Generalized Proximity Ligation Method.
M. Jarvius, J. Paulsson, I. Weibrecht, K.-J. Leuchowius, A.-C. Andersson, C. Wahlby, M. Gullberg, J. Botling, T. Sjoblom, B. Markova, et al. (2007)
Mol. Cell. Proteomics 6, 1500-1509
   Abstract »    Full Text »    PDF »
Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF.
S. C. Kiley and R. L. Chevalier (2007)
Am J Physiol Renal Physiol 293, F895-F903
   Abstract »    Full Text »    PDF »
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.
C. Peng, J. Brain, Y. Hu, A. Goodrich, L. Kong, D. Grayzel, R. Pak, M. Read, and S. Li (2007)
Blood 110, 678-685
   Abstract »    Full Text »    PDF »
s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis.
J. Li, R. Berbeco, R. J. Distel, P. A. Janne, L. Wang, and G. M. Makrigiorgos (2007)
Nucleic Acids Res. 35, e84
   Abstract »    Full Text »    PDF »
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms.
H. Y. Zou, Q. Li, J. H. Lee, M. E. Arango, S. R. McDonnell, S. Yamazaki, T. B. Koudriakova, G. Alton, J. J. Cui, P.-P. Kung, et al. (2007)
Cancer Res. 67, 4408-4417
   Abstract »    Full Text »    PDF »
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer.
M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. Matias-Guiu, S. Ramon y Cajal, J. Arribas, et al. (2007)
J Natl Cancer Inst 99, 628-638
   Abstract »    Full Text »    PDF »
A Selective Small Molecule Inhibitor of c-Met, PHA665752, Inhibits Tumorigenicity and Angiogenesis in Mouse Lung Cancer Xenografts.
N. Puri, A. Khramtsov, S. Ahmed, V. Nallasura, J. T. Hetzel, R. Jagadeeswaran, G. Karczmar, and R. Salgia (2007)
Cancer Res. 67, 3529-3534
   Abstract »    Full Text »    PDF »
Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor.
P. Steiner, C. Joynes, R. Bassi, S. Wang, J. R. Tonra, Y. R. Hadari, and D. J. Hicklin (2007)
Clin. Cancer Res. 13, 1540-1551
   Abstract »    Full Text »    PDF »
PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors.
I. K. Mellinghoff, T. F. Cloughesy, and P. S. Mischel (2007)
Clin. Cancer Res. 13, 378-381
   Abstract »    Full Text »    PDF »
Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b.
G. K. Scott, A. Goga, D. Bhaumik, C. E. Berger, C. S. Sullivan, and C. C. Benz (2007)
J. Biol. Chem. 282, 1479-1486
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882